The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trial.

Jie Yu,Arianne N Sweeting, Chris Gianacas,Lauren Houston,Vivian Lee,Robert A Fletcher,Vlado Perkovic,Qiang Li,Brendon L Neuen, Otavio Berwanger,Hiddo J L Heerspink,Dick de Zeeuw,Clare Arnott

Diabetes, obesity & metabolism（2023）

引用 0|浏览12

暂无评分

摘要

The cardiovascular and renal benefits of canagliflozin and its safety profile were consistent across population-specific BMI subgroups for adults in the CANVAS Program and CREDENCE trial.

查看译文

关键词

canagliflozin, cardiovascular disease, clinical trial, SGLT2 inhibitor, obesity therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要